Effect of disodium cromoglycate (Intal) on sputum protein composition

SANDRA HEILPERN and A. S. REBUCK

Thoracic Unit, The Royal North Shore Hospital of Sydney and Department of Medicine, The University of Sydney, Sydney, Australia

The protein content in the sputum of nine patients with asthma was compared with that in 11 non-asthmatic patients by a method of gel electrophoresis. It was found that the albumin content was significantly higher in the sputum of the asthmatics than of the non-asthmatics (P<0.01). A further 11 asthmatic patients who were taking disodium cromoglycate (Intal) as part of their treatment had sputum albumin levels indistinguishable from the non-asthmatics. When patients with asthma were then studied serially, before and after disodium cromoglycate therapy, the albumin content returned to non-asthmatic levels within two days of starting treatment. It is suggested that disodium cromoglycate has a previously unrecognized action in altering sputum proteins.

Methods have now been developed for investigating the biochemical characteristics of bronchial mucus (Ryley and Brogan, 1968) as well as sputum viscosity (Cobbin, Elliott, and Rebuck, 1969) in patients with asthma and chronic lung disease.

Sputum production in asthma is markedly decreased in patients treated with disodium cromoglycate (Intal). This drug prevents asthmatic attacks attributable to precipitins (Pepys, Hargreave, Chan, and McCarthy, 1968) as well as having a steroid-sparing effect (Read and Rebuck, 1969).

Although various proteins in the sputum of patients with asthma have been studied, and compared with those of normal subjects (Newcomb and DeVald, 1969; Dennis, Hornbrook, and Ishizaka, 1964), the effect of disodium cromoglycate on protein characteristics has not been studied. The aim of this investigation was to assess the effect of the drug on sputum protein content in patients with asthma.

PATIENTS AND METHODS

Thirty-four patients were studied, all of whom were treated in the Thoracic Unit of the Royal North Shore Hospital of Sydney. We divided them into four groups according to the following clinical criteria:

GROUP A Nine patients with bronchial asthma, none of whom was using disodium cromoglycate. There were five men and four women, whose ages ranged from 35 to 67 (mean 56) years.

GROUP B Nine patients with asthma who had been using disodium cromoglycate (4 capsules daily) for two or more days. This group consisted of four men and five women aged 19 to 67 (mean 35) years.

GROUP C Eleven patients with chronic cardiac or pulmonary disease, but not asthma. Six were men and five women, whose ages ranged from 27 to 62 (mean 53) years.

GROUP D These five patients, all female, had asthma, and were tested both before and after starting disodium cromoglycate therapy, so that they were able to act as their own controls. Their ages ranged from 17 to 46 (mean 34) years.

In no case was bloodstained sputum studied, and patients whose sputum showed bacteriological evidence of pathogenic infection were eliminated from the trial.

Sputum samples consisted of the total sputum produced by patients during the first four hours after waking. The samples were expectorated directly into jars containing 10 ml tris-glycine buffer at pH 8-3.

The gel fraction was separated by straining the sputum through gauze for 30 minutes. Gel was then scraped from the gauze and its volume was measured. Gel viscosity was reduced with 0.075 M cysteine in 1/15 M phosphate buffer at pH 7-5, after which it was incubated at 37°C for two hours (Havez, Roussel, Degand, and Biserte, 1967). After dialysis at 4°C for five to seven days, the specimen was centrifuged at 15,000 rev/min for 30 minutes, and the supernatant was used for further testing.
**Effect of disodium cromoglycate (Intal) on sputum protein composition**

**TABLE**

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>Total Protein (mg%)</th>
<th>Per cent Albumin</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (asthma)</td>
<td>412 (SD=162)</td>
<td>29·5 (SD=7·6)</td>
</tr>
<tr>
<td>B (asthma + Intal)</td>
<td>743 (SD=728)</td>
<td>16·0 (SD=7·6)</td>
</tr>
<tr>
<td>C (non-asthmatic)</td>
<td>282 (SD=147)</td>
<td>17·1 (SD=6·4)</td>
</tr>
<tr>
<td>D (asthma before and after Intal)</td>
<td>+116 (SD = 59)</td>
<td>-8·9 (SD = 4·1)</td>
</tr>
</tbody>
</table>

SD = ± standard deviation

1 mg% of drained gel fraction of sputum

patients, serial studies of sputum proteins were made over several days during which disodium cromoglycate therapy was introduced. Within two days of starting therapy, there was a significant decrease in albumin concentration \( (P<0·02) \) accompanied by an increase in total protein \( (P<0·02) \). These results are summarized in the Table.

**DISCUSSION**

This study offers clear evidence that the protein characteristics of the sputum of patients with asthma differ from those of patients with other forms of lung disease. Like Brogan, Ryley, Allen, and Hutt (1971), we have shown that this difference can be identified in the albumin concentration. In patients with asthma there is a significant increase in the relative albumin concentration in the sputum. Brogan et al. felt that the proportion of albumin in sputum sol phase high-molecular-weight substances might hold promise as a criterion for distinguishing between asthma and chronic bronchitis.

Disodium cromoglycate (Intal) was tested because it was known that it had a marked clinical effect on the sputum of patients with asthma. We have found that disodium cromoglycate converts the albumin concentration in the sputum of asthmatics to levels found in non-asthmatic subjects. In estimating the percentage of albumin in the sputum of the asthmatics only small samples were available for assessing total protein as the sputum volume had been reduced following treatment with disodium cromoglycate. This extreme reduction in the volume and gel content of the sputum in these patients necessitated the use of the Lowry method of protein estimation which requires only one-tenth of the volume of prepared sputum, compared with the more widely used Biuret method.

It is unlikely that salivary contamination played a role in influencing these results. Like Ryley and Brogan (1968), we used drainage on cotton gauze.
and low-speed centrifugation to remove saliva from test substances. In addition, the sputum was always expectorated into pH 8.3 buffer, in the belief that this would minimize digestion of sputum glycoproteins by salivary amylase, even though there is little experimental evidence that this would be the case. It could be said that the use of the buffer for collection of samples has permitted some diffusion of soluble proteins into the surrounding buffer. However, the same procedure was used for each group, and differences were significant between groups, indicating a lower percentage of albumin in the treated sputum of asthmatics taking disodium cromoglycate, compared with the treated sputum of asthmatics not taking the drug.

It could also be said that the total protein estimations and the electrophoresis performed on the treated samples were only semi-quantitative due to intrinsic proteolysis and resulting protein loss during sample preparation. However, the results of this study are based on the per cent that albumin represented of the total protein of the chromatogram. Hence absolute values were not used in comparing the groups.

It is possible that the present study has thrown further light on the mode of action of disodium cromoglycate in asthma. The drug prevents the release of chemical mediators resulting from antigen-reagin reactions (Orange and Austen, 1968), and, as might be expected, it is of considerable benefit to patients with asthma of allergic origin.

However, many patients in whom no 'allergic' origin can be identified appear to benefit from disodium cromoglycate. For example, Davies (1968) has demonstrated that the drug will prevent episodes of exercise-induced asthma, in which it is hard to imagine any allergic reaction playing a significant triggering role.

This study does not attempt to explain why disodium cromoglycate is also effective in non-allergic asthma. However, the evidence points to a previously unrecognized action of the drug, that of lowering albumin concentration in sputum to levels found in non-asthmatic patients. The significance of this finding awaits further study.

This work was supported by a research grant by Fisons Pty Ltd. The authors wish to thank Dr. W. Allan Crawford, O.B.E., M.B., Ch.B., Ph.D., for encouragement in the conduct of this work, and Dr. J. Margolis for helpful advice.

REFERENCES


Effect of disodium cromoglycate (Intal) on sputum protein composition
Sandra Heilpern and A. S. Rebuck

Thorax 1972 27: 726-728
doi: 10.1136/thx.27.6.726

Updated information and services can be found at:
http://thorax.bmj.com/content/27/6/726

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/